Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

23Andme Holding Co. - news published 264 - readings 8.748

BACK

23Andme Holding Co.

Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on March 23, 2025, 23andMe Holding Co., a Delaware corporation (the "Company"), and certain of its subsidiaries (collectively, the "Filing Subsidiaries" and, together with the Company, the "Debtors") filed volun ...

28.03.2025

23Andme Holding Co.

Initial Statement of Beneficial Ownership (Form 3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 (Print or Type Responses) 1. Nam ...

26.03.2025

23Andme Holding Co.

Initial Statement of Beneficial Ownership (Form 3)

26.03.2025

23Andme Holding Co.

Material Agreement, Bankruptcy, Regulation FD Presentation, Management Change/Compensation (Form 8-K)

Filing Subsidiaries No. Entity Name State of Incorporation 1. 23andMe Holding Co. Delaware 2. 23andMe, Inc. Delaware 3. Lemonaid Health, Inc. Delaware 4. 23andMe Pharmacy Holdings, Inc. Delaware 5. Lemonaid Pharmacy Holdings Inc. Delaware 6. Lemonaid Community Pharmacy, Inc. Missouri 7. LPharm INS LLC Delaware 8. LPharm CS LLC Delaware 9. LPharm RX LLC Delaware 10. LPRXOne LLC ...

24.03.2025

23Andme Holding Co.

23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court- Supervised Sale Process March 24, 2025 Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financi ...

24.03.2025

23Andme Holding Co.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

21.02.2025

23Andme Holding Co.

Quarterly Report for Quarter Ending December 31, 2024 (Form 10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

06.02.2025

23Andme Holding Co.

23andMe Reports Third Quarter Fiscal Year 2025 Financial Results (Form 8-K)

23andMe Reports Third Quarter Fiscal Year 2025 Financial Results Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., January 28, 2025 -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe," the "Company," "we," "us," and "our"), a le ...

28.01.2025

23Andme Holding Co.

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES A ...

21.11.2024

23Andme Holding Co.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

me-20240930 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

12.11.2024

23Andme Holding Co.

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results Form 8 K

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results SUNNYVALE, Calif., November. 12, 2024 -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: •Improved GAAP Net Loss by 21% and Adjusted EBITDA by ...

12.11.2024

23Andme Holding Co.

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer 23Andme Holding Co. published this content on November 12, 2024 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 12, 2024 at 12:34:50.902 .

12.11.2024

23Andme Holding Co.

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future November 11, 2024 Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs SUNNYVALE, Calif., No ...

11.11.2024

23Andme Holding Co.

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer 23Andme Holding Co. published this content on November 07, 2024 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 08, 2024 at 03:41:37.249 .

08.11.2024

23Andme Holding Co.

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer 23Andme Holding Co. published this content on November 07, 2024 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 07, 2024 at 23:51:30.539 .

07.11.2024

23Andme Holding Co. - news published 264 - readings 8.748

23Andme Holding Co.

Failure to Satisfy Listing Rule (Form 8-K)

23Andme Holding Co.

Initial Statement of Beneficial Ownership (Form 3)

23Andme Holding Co.

Initial Statement of Beneficial Ownership (Form 3)

23Andme Holding Co.

Material Agreement, Bankruptcy, Regulation FD Presentation, Management Change/Compensation (Form 8-K)

23Andme Holding Co.

23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

23Andme Holding Co.

Statement of Changes in Beneficial Ownership (Form 4)

23Andme Holding Co.

Quarterly Report for Quarter Ending December 31, 2024 (Form 10-Q)

23Andme Holding Co.

23andMe Reports Third Quarter Fiscal Year 2025 Financial Results (Form 8-K)

23Andme Holding Co.

Statement of Changes in Beneficial Ownership - Form 4

23Andme Holding Co.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

23Andme Holding Co.

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results Form 8 K

23Andme Holding Co.

23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

23Andme Holding Co.

23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

23Andme Holding Co.

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

23Andme Holding Co.

CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member